Lisuride treatment of Restless Legs Syndrome: first studies with monotherapy in de novo patients and in combination with levodopa in advanced disease

Beneŝ, Heike; Deissler, A.; Rodenbeck, Andrea; Engfer, Anette; Kohnen, Ralf

doi:10.1007/s00702-005-0386-1

Cited by 21 publications

(11 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two small pilot studies providing Class III evidence found lisuride transdermal patch 3 and 6 mg to improve IRLS scores and to improve PLMI as measured using actigraphy. Lisuride is not currently on the market for the treatment for RLS.…”

Section: Resultsmentioning

confidence: 99%

European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society

Garcı́a-Borreguero¹,

Ferini‐Strambi

Kohnen³

et al. 2012

Euro J of Neurology

138

View full text Add to dashboard Cite

Background: Since the publication of the first European Federation of Neurological Societies (EFNS) guidelines in 2005 on the management of restless legs syndrome (RLS; also known as Willis-Ekbom disease), there have been major therapeutic advances in the field. Furthermore, the management of RLS is now a part of routine neurological practice in Europe. New drugs have also become available, and further randomized controlled trials have been undertaken. These guidelines were undertaken by the EFNS in collaboration with the European Neurological Society and the European Sleep Research Society. Objectives: To provide an evidence-based update of new treatments published since 2005 for the management of RLS. Methods: First, we determined what the objectives of management of primary and secondary RLS should be. We developed the search strategy and conducted a review of the scientific literature up to 31 December 2011 (print and electronic publications) for the drug classes and interventions employed in RLS treatment. Previous guidelines were consulted. All trials were analysed according to class of evidence, and recommendations made according to the 2004 EFNS criteria for rating. Recommendations: Level A recommendations can be made for rotigotine, ropinirole, pramipexole, gabapentin enacarbil, gabapentin and pregabalin, which are all considered effective for the short-term treatment for RLS. However, for the long-term 1385European Journal of Neurology 2012Neurology , 19: 1385Neurology -1396Neurology doi:10.1111Neurology /j.1468Neurology -1331Neurology .2012 treatment for RLS, rotigotine is considered effective, gabapentin enacarbil is probably effective, and ropinirole, pramipexole and gabapentin are considered possibly effective. Cabergoline has according to our criteria a level A recommendation, but the taskforce cannot recommend this drug because of its serious adverse events.

show abstract

Section: Resultsmentioning

confidence: 99%

European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society

Garcı́a-Borreguero¹,

Ferini‐Strambi

Kohnen³

et al. 2012

Euro J of Neurology

138

View full text Add to dashboard Cite

show abstract

“…1996; Egan et al, 1998; Marona-Lewicka et al, 2002; Millan et al, 2002; Nichols et al, 2002). Despite the fact that lisuride has high affinity for the 5-HT 2A receptor and acts as an agonist (Egan et al 1998; Kurrasch-Orbaugh et al, 2003b; Cussac et al, 2008), it is not hallucinogenic in humans (Herrmann et al, 1977; Verde et al, 1980; Raffaelli et al, 1983; Beneš et al, 2006) and has been used clinically to treat migraine and Parkinson's disease. Some studies have found that lisuride produces full substitution in rats trained with either LSD, DOI, or DOM (White and Appel, 1982; Glennon and Hauck, 1985; Fiorella et al, 1995b; Appel et al, 1999), but in other studies it produced only partial substitution (Holohean et al,1982; Marona-Lewicka et al, 2002).…”

Section: Involvement Of the 5-ht2a Receptor In Hallucinogen Effectsmentioning

confidence: 99%

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens

Halberstadt

2015

Behavioural Brain Research

248

203

View full text Add to dashboard Cite

Serotonergic hallucinogens, such as (+)-lysergic acid diethylamide, psilocybin, and mescaline, are somewhat enigmatic substances. Although these drugs are derived from multiple chemical families, they all produce remarkably similar effects in animals and humans, and they show cross-tolerance. This article reviews the evidence demonstrating the serotonin 5-HT2A receptor is the primary site of hallucinogen action. The 5-HT2A receptor is responsible for mediating the effects of hallucinogens in human subjects, as well as in animal behavioral paradigms such as drug discrimination, head twitch response, prepulse inhibition of startle, exploratory behavior, and interval timing. Many recent clinical trials have yielded important new findings regarding the psychopharmacology of these substances. Furthermore, the use of modern imaging and electrophysiological techniques is beginning to help unravel how hallucinogens work in the brain. Evidence is also emerging that hallucinogens may possess therapeutic efficacy.

show abstract

“…The ergoline derivative lisuride is a structural analog of LSD that shows a similar binding profile at monoamine receptors. Although lisuride acts as a 5-HT 2A agonist (Egan et al 1998; Kurrasch-Orbaugh et al 2003; Cussac et al 2008), it does not produce hallucinogenic effects (Herrmann et al 1977; Verde et al 1980; Raffaelli et al 1983; Benes et al 2006). Nevertheless, lisuride produces false-positive results in some animal models used to study hallucinogens.…”

Section: Head Twitch Responsementioning

confidence: 99%

Effect of Hallucinogens on Unconditioned Behavior

Halberstadt

Geyer

2016

Behavioral Neurobiology of Psychedelic Drugs

View full text Add to dashboard Cite

Because of the ethical and regulatory hurdles associated with human studies, much of what is known about the psychopharmacology of hallucinogens has been derived from animal models. However, developing reliable animal models has proven to be a challenging task due to the complexity and variability of hallucinogen effects in humans. This chapter focuses on three animal models that are frequently used to test the effects of hallucinogens on unconditioned behavior: head twitch response (HTR), prepulse inhibition of startle (PPI), and exploratory behavior. The HTR has demonstrated considerable utility in the neurochemical actions of hallucinogens. However, the latter two models have clearer conceptual bridges to human phenomenology. Consistent with the known mechanism of action of hallucinogens in humans, the behavioral effects of hallucinogens in rodents are mediated primarily by activation of 5-HT receptors. There is evidence, however, that other receptors may play secondary roles. The structure-activity relationships (SAR) of hallucinogens are reviewed in relation to each model, with a focus on the HTR in rats and mice.

show abstract

Lisuride treatment of Restless Legs Syndrome: first studies with monotherapy in de novo patients and in combination with levodopa in advanced disease

Cited by 21 publications

References 10 publications

European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society

European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens

Effect of Hallucinogens on Unconditioned Behavior

Contact Info

Product

Resources

About